Search tips
Search criteria 


Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
J Virol. 2007 August; 81(16): 8838–8842.
Published online 2007 May 30. doi:  10.1128/JVI.02663-06
PMCID: PMC1951355

Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease[down-pointing small open triangle]


Long-term asymptomatic human immunodeficiency virus (HIV)-infected individuals (LTA) usually have low viral load and low immune activation. To discern whether viral load or immune activation is dominant in determining progression to AIDS, we studied three exceptional LTA with high viral loads. HIV type 1 isolates from these LTA were as pathogenic as viruses from progressors in organ culture. Despite high viral loads, these LTA had low levels of proliferating and activated T cells compared to progressors, like other LTA. In contrast to those in progressors, HIV-specific CD4+ T-cell responses in these LTA were maintained. Thus, low immune activation despite a high viral load preserved HIV-specific T-cell responses and resulted in a long-term asymptomatic phenotype.

Both viral load and immune activation have been shown to be associated with progression to AIDS (2, 5-8, 11, 12). Since immune activation and viral load are correlated (2, 5, 6, 8), it is hard to determine which factor is dominant in determining disease progression. To further elucidate the importance of immune activation relative to viral load in human immunodeficiency virus (HIV) disease progression, we studied three rare long-term-asymptomatic HIV-infected individuals (LTA) from the Amsterdam Cohort Studies on HIV infection and AIDS who have high viral loads (LTA-HVL) equal to the viral loads seen in progressors (Fig. (Fig.11).

FIG. 1.
Longitudinal analysis of CD4+ T-cell numbers in blood and HIV-1 RNA copies in plasma of the patients used in this study. Plasma viral RNA copies per ml (left axes; large symbols and dashed lines) and CD4+ T cells per μl blood (right ...

Although the high viral loads of these LTA-HVL were consistent with a high replicative capacity of isolated virus clones in vitro (1), slow disease progression despite high viral load may be caused by a decreased pathogenic phenotype of the virus. We tested the cytopathic effects (CPE) of these viruses in human fetal thymic organ culture (FTOC) as described previously (3). The time points of viral isolation used in these assays are indicated in Fig. Fig.1.1. Pieces of thymic tissue (8 mm3) were infected with 8 × 103 50% tissue culture infective doses of HIV type 1 (HIV-1) clones derived from progressors, LTA, or LTA-HVL. Viral replication and percentages of CD4+ and CD8+ thymocytes were assayed over a 3-week time period by p24 enzyme-linked immunosorbent assay and flow cytometry with CD4-phycoerythrin and CD8-peridinin chlorophyll protein monoclonal antibodies, respectively. In mock-infected FTOC, approximately, 78% of light scatter-gated thymocytes expressed CD4 at 14 and 21 days postinfection (Fig. (Fig.2A).2A). Both progressor- and LTA-HVL-derived R5-HIV-1 clones caused depletion of more than 35% of CD4+ thymocytes compared to that in mock infection at 21 days postinfection (P < 0.001) (statistical significance was determined by analysis of variance with Tukey's test for all pairwise comparisons). Likewise, both progressor- and LTA-HVL-derived R5-HIV-1 clones replicated to similar levels, except clones from LTA-HVL patient 68, in which replication peaked later in the course of infection (Fig. (Fig.2B).2B). In contrast, R5-HIV-1 clones derived from LTA with low viral loads failed to exhibit significant CPE and replicated poorly.

FIG. 2.
R5-HIV-1 clones from LTA-HVL replicated to high levels and depleted CD4+ thymocytes in FTOC. FTOCs were infected with the indicated HIV-1 clones. (A) The bars represent average percentages of CD4+ thymocytes (CD4SP and -DP) in FTOC, with ...

Next we tested the ability of progressor- and LTA-HVL-derived R5-HIV-1 clones to deplete CD4+ T cells in secondary lymphoid tissue histoculture. Lymphocytes were isolated from human spleen histoculture on days 16 and 21 postinfection with HIV-1 clones derived from progressors or LTA-HVL, stained with CD4-phycoerythrin and CD8-peridinin chlorophyll protein monoclonal antibodies, and analyzed by flow cytometry with a lymphocyte gate based on 90° and low-angle light scatter. Again, progressor- and LTA-HVL-derived R5-HIV-1 clones depleted CD4+ T cells significantly (P < 0.0001) compared to mock-infected tissue on both days 16 and day 21, as measured by the ratio of CD4+ to CD8+ cells (Fig. (Fig.3A).3A). No statistical difference in CPE was observed between progressor- and LTA-HVL-derived clones in FTOC or in spleen histoculture. As expected, the R5-HIV-1 clones preferentially depleted CD4+ CCR5+ T cells, while the X4-HIV-1 molecular clone NL4-3 depleted the CD4+ CXCR4+ subset of T cells more efficiently (Fig. 3B and C). These results show that R5-HIV-1 clones obtained from LTA-HVL were equally replication competent and cytopathic as progressor-derived clones. Therefore, the replication and CPE of these R5-HIV-1 clones in primary and secondary lymphoid tissue organ culture were not reflective of the clinical status of the patients from which they were derived.

FIG. 3.
Depletion of CD4+ cells in human spleen histoculture infected ex vivo with HIV-1. Spleen histocultures were infected with the indicated HIV-1 clones. (A) Depletion of CD4+ lymphocytes measured by change in the ratio of CD4+ to ...

We hypothesized that the LTA-HVL showed slow disease progression due to low-level immune activation despite a high viral load, since high levels of activated and proliferating (Ki67+) CD4+ and CD8+ T cells during HIV infection are better prognostic factors than viral load (5, 6, 8) and preseroconversion immune activation has been shown to be predictive of disease progression (8, 15, 16). Moreover, patients who fail virologically on highly active antiretroviral therapy but have low levels of T-cell activation, proliferation, and apoptosis show a continuous increase in CD4+ T cells (4, 9, 13). Similarly, during natural simian immunodeficiency virus infection, sooty mangabeys do not develop disease despite high viral loads, and their immune activation is as low as that in uninfected animals. In contrast, pathogenic simian immunodeficiency virus infection in macaques induces strong immune activation, CD4+ T-cell loss, and disease progression (14). Collectively these data implicate immune activation as a driving force of HIV pathogenesis.

To test this hypothesis, we longitudinally followed the immune activation status (measured as previously described [8]) of the three LTA-HVL and compared these values with those for progressors matched for HIV viral load and for LTA with low viral loads (Fig. (Fig.1).1). The time points measured were approximately 1 year, 5 years, and for LTA-HVL additionally 11 years after seroconversion or seropositive entry into the cohort. The time-points used for analysis are indicated in Fig. Fig.11.

Progressors showed high percentages of activated HLA-DR+ CD38+ CD4+ and CD8+ T cells within 5 years of HIV-1 infection. In contrast, the LTA-HVL had levels of activated T cells comparable to those of LTA with low viral loads even after more than 10 years of HIV-1 infection. A similar trend was found for proliferating, Ki67-expressing CD4+ and CD8+ T cells (Fig. (Fig.4A).4A). The levels of proliferating T cells of both subsets was significantly lower in LTA and in LTA-HVL than in progressors at later time points by Tukey's test.

FIG. 4.
LTA-HVL had low immune activation and preserved HIV-specific responses. (A) Percentages of activated (CD38+ HLA-DR+) and proliferating (Ki67+) CD4+ and CD8+ T cells. (B) Absolute numbers of HIV-specific IL-2-producing ...

Jansen et al. (10) have shown that HIV-specific CD4+ T-cell responses soon after seroconversion did not have predictive power for disease progression in a prospective cohort study in a multivariate analysis including immune activation. HIV-specific CD4+ T-cell responses were lost over time in progressors, however, compared to LTA. To further elucidate whether loss of HIV-specific CD4+ T cell responses was due to high viral load or to high-level immune activation, we determined absolute numbers of Gag-specific gamma interferon (IFN-γ)- and interleukin-2 (IL-2)-producing CD4+ T cells (measured as previously described [10]). Gag-specific IFN-γ- and IL-2-producing CD4+ T cells were readily detected early after infection in all subjects (Fig. (Fig.4B).4B). These responses, while preserved in LTA with both high and low viral loads, however, tended to decrease over time in progressors. The effect was pronounced for absolute numbers of IL-2- and IFN-γ-producing CD4+ T cells (Fig. (Fig.4B)4B) but did not achieve statistical significance with only three patients in each group. When six more progressors studied previously were included in the comparison (10), however, the Gag-specific IFN-γ response of the LTA-HVL at time points B and C was significantly different from that of progressors at time point B, and the IL-2 response approached a significant difference (P = 0.03 and 0.07, respectively, by Student's t test). This suggests that it is not high viral load alone but instead chronic immune activation with high viral load that causes loss of functional Gag-specific CD4+ T cells over time.

In summary, despite high viral loads, HIV-1 infection did not evoke high levels of immune activation or proliferation in these LTA-HVL. Although few patients could be studied, these data provide additional support for the idea that chronic immune activation is an important driving force for CD4+ T-cell decline and loss of HIV-specific CD4+ T-cell responses in HIV-1-infected individuals. Moreover, these data suggest that if there were no effective vaccine or treatment for AIDS, humans might eventually evolve resistance to HIV-1 by one of two mechanisms, exemplified by LTA, who suppress viral replication, and LTA-HVL, whose immune systems are not nonspecifically activated by HIV-1 infection.


We thank Argyrios Ziogas of the University of California, Irvine, for help with statistical analyses of the data.

We acknowledge support from NIH grant AI-55385 awarded to D.C. and the Amsterdam Cohort Studies on HIV Infection and AIDS, a collaboration between the Amsterdam Health Service, the Academic Medical Center of the University of Amsterdam, the Sanquin Blood Supply Foundation, and the University Medical Center Utrecht, part of The Netherlands HIV Monitoring Foundation, which is financially supported by The Netherlands National Institute for Public Health and the Environment.


[down-pointing small open triangle]Published ahead of print on 30 May 2007.


1. Blaak, H., M. Brouwer, L. J. Ran, F. De Wolf, and H. Schuitemaker. 1998. In vitro replication kinetics of HIV-1 variants in relation to viral load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177:600-610. [PubMed]
2. Carbone, J., J. Gil, J. M. Benito, J. Navarro, A. Muñóz-Fernández, J. Bartolomé, J. M. Zabay, F. López, and E. Fernández-Cruz. 2000. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 14:2823-2829. [PubMed]
3. Choudhary, S. K., N. R. Choudhary, K. C. Kimbrell, J. Colasanti, A. Ziogas, D. Kwa, H. Schuitemaker, and D. Camerini. 2005. R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression 2. J. Virol. 79:458-471. [PMC free article] [PubMed]
4. Deeks, S. G., R. Hoh, R. M. Grant, T. Wrin, J. D. Barbour, A. Narvaez, D. Cesar, K. Abe, M. B. Hanley, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, and M. K. Hellerstein. 2002. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185:315-323. [PubMed]
5. Deeks, S. G., C. M. Kitchen, L. Liu, H. Guo, R. Gascon, A. B. Narvaez, P. Hunt, J. N. Martin, J. O. Kahn, J. Levy, M. S. McGrath, and F. M. Hecht. 2004. Immune activation set point during early HIV infection predicts subsequent CD4+ T cell changes independent of viral load. Blood 104:942-947. [PubMed]
6. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, S. M. Wolinsky, and R. Detels. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870. [PubMed]
7. Giorgi, J. V., Z. Liu, L. E. Hultin, W. G. Cumberland, K. Hennessey, R. Detels, et al. 1993. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J. Acquir. Immune Defic. Syndr. 6:904-912. [PubMed]
8. Hazenberg, M. D., S. A. Otto, B. H. van Benthem, M. T. Roos, R. A. Coutinho, J. M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17:1881-1888. [PubMed]
9. Hazenberg, M. D., S. A. Otto, F. W. N. M. Wit, J. M. A. Lange, D. Hamann, and F. Miedema. 2002. Discordant responses during antiretroviral therapy: role for immune activation and T cell redistribution. AIDS 16:1287-1289. [PubMed]
10. Jansen, C. A., I. M. De Cuyper, B. Hooibrink, A. K. van der Bij, D. van Baarle, and F. Miedema. 2006. Prognostic value of HIV-1 Gag-specific CD4+ T cell responses for progression to AIDS analysed in a prospective cohort study. Blood 107:1427-1433. [PubMed]
11. Liu, Z., W. G. Cumberland, L. E. Hultin, H. E. Prince, R. Detels, and J. V. Giorgi. 1997. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune Defic. Syndr. 16:83-92.
12. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170. [PubMed]
13. Meroni, L., S. Varchetta, D. Manganaro, N. Gatti, A. Riva, A. Monforte, and M. Galli. 2002. Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors. J. Infect. Dis. 186:143-144. [PubMed]
14. Silvestri, G., D. L. Sodora, R. A. Koup, M. Paiardini, S. P. O'Neil, H. M. McClure, S. I. Staprans, and M. B. Feinberg. 2003. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18:441-452. [PubMed]
15. Simmonds, P., D. Beatson, R. J. G. Cuthbert, H. Watson, B. Reynolds, J. F. Peutherer, J. V. Parry, C. A. Ludlam, and C. M. Steel. 1991. Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 338:1159-1163. [PubMed]
16. Van Asten, L., F. Danisman, S. A. Otto, J. A. Borghans, M. D. Hazenberg, R. A. Coutinho, M. Prins, and F. Miedema. 2004. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS 18:1885-1893. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)